一名接受尼洛替尼治疗的慢性髓性白血病患者发生T细胞原淋巴细胞白血病：首例文献报道 - Suppr

T-cell prolymphocytic leukaemia in a patient with chronic myeloid leukaemia receiving nilotinib: first documented report.

作者信息

Hanley Brian, Nesr George, Yebra-Fernandez Eva, Brown Loretta, Rabitsch Andrea, Killeen Natalie, Claudiani Simone, Milojkovic Dragana, Kanfer Edward, Apperley Jane, Naresh Kikkeri N

机构信息

Cellular Pathology, Imperial College London NHS Trust, London, United Kingdom.

Imperial College Healthcare NHS Trust, London, United Kingdom.

出版信息

J Clin Pathol. 2019 Jul;72(7):511-512. doi: 10.1136/jclinpath-2019-205799. Epub 2019 Apr 19.

DOI:10.1136/jclinpath-2019-205799

PMID:31004076

Abstract

摘要

相似文献

T-cell prolymphocytic leukaemia in a patient with chronic myeloid leukaemia receiving nilotinib: first documented report.一名接受尼洛替尼治疗的慢性髓性白血病患者发生T细胞原淋巴细胞白血病：首例文献报道

J Clin Pathol. 2019 Jul;72(7):511-512. doi: 10.1136/jclinpath-2019-205799. Epub 2019 Apr 19.

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.尼洛替尼与伊马替尼治疗新诊断的费城染色体阳性慢性期慢性髓性白血病患者：3 期随机 ENESTnd 试验的 24 个月最小随访。

Lancet Oncol. 2011 Sep;12(9):841-51. doi: 10.1016/S1470-2045(11)70201-7. Epub 2011 Aug 17.

Bullous sweet syndrome in a patient with t(9;22)(q34;q11)-positive chronic myeloid leukemia treated with the tyrosine kinase inhibitor nilotinib: interphase cytogenetic detection of BCR-ABL- positive lesional cells.用酪氨酸激酶抑制剂尼罗替尼治疗的t(9;22)(q34;q11)阳性慢性髓性白血病患者发生大疱性Sweet综合征：BCR-ABL阳性病变细胞的间期细胞遗传学检测

Arch Dermatol. 2008 Mar;144(3):361-4. doi: 10.1001/archderm.144.3.361.

Chronic myeloid leukemia with a novel e8a1 BCR-ABL1 fusion: rapid molecular response with nilotinib.伴有新型e8a1 BCR-ABL1融合的慢性髓性白血病：尼洛替尼治疗后的快速分子反应

Leuk Lymphoma. 2017 Sep;58(9):1-6. doi: 10.1080/10428194.2017.1281413. Epub 2017 Jan 25.

Development of psoriasis in a patient with chronic myelogenous leukaemia during nilotinib treatment.尼洛替尼治疗期间慢性髓性白血病患者出现银屑病。

Eur J Haematol. 2013 Sep;91(3):270-272. doi: 10.1111/ejh.12153. Epub 2013 Jun 28.

Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.尼洛替尼300毫克每日两次用于对既往酪氨酸激酶抑制剂不耐受的慢性期慢性髓性白血病患者的疗效和安全性：IIIb期ENESTswift研究结果

Leuk Res. 2018 Apr;67:109-115. doi: 10.1016/j.leukres.2018.02.013. Epub 2018 Feb 21.

Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.达沙替尼用于治疗伊马替尼治疗失败后的费城染色体阳性慢性髓性白血病。

Expert Opin Pharmacother. 2007 Dec;8(18):3257-64. doi: 10.1517/14656566.8.18.3257.

Optimal Response in a Patient With CML Expressing E6A2 Fusion Transcript With Nilotinib Therapy: A Case Report.尼洛替尼治疗表达 E6A2 融合转录本的 CML 患者的最佳反应：病例报告。

In Vivo. 2020 May-Jun;34(3):1481-1486. doi: 10.21873/invivo.11933.

Nilotinib can override dasatinib resistance in chronic myeloid leukemia patients with secondary resistance to imatinib first-line therapy.尼罗替尼可克服对伊马替尼一线治疗继发耐药的慢性髓性白血病患者的达沙替尼耐药性。

Acta Haematol. 2007;118(3):162-4. doi: 10.1159/000108639. Epub 2007 Sep 20.

Nilotinib: in the first-line treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase.尼洛替尼：用于治疗新诊断的费城染色体阳性慢性期慢性髓性白血病的一线治疗药物。

Drugs. 2011 Aug 20;71(12):1579-90. doi: 10.2165/11207770-000000000-00000.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

T-cell prolymphocytic leukaemia in a patient with chronic myeloid leukaemia receiving nilotinib: first documented report.

作者信息

机构信息

出版信息

相似文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献